Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2025)
Historic Equity Average for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $7.6 billion.
- Teva Pharmaceutical Industries' Equity Average rose 2894.67% to $7.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 billion, marking a year-over-year increase of 2894.67%. This contributed to the annual value of $6.6 billion for FY2025, which is 156.97% down from last year.
- As of Q4 2025, Teva Pharmaceutical Industries' Equity Average stood at $7.6 billion, which was up 2894.67% from $7.0 billion recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Equity Average high stood at $11.4 billion for Q3 2021, and its period low was $5.8 billion during Q1 2025.
- For the 5-year period, Teva Pharmaceutical Industries' Equity Average averaged around $8.5 billion, with its median value being $7.9 billion (2023).
- Per our database at Business Quant, Teva Pharmaceutical Industries' Equity Average crashed by 2568.21% in 2021 and then skyrocketed by 2894.67% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Equity Average (Quarter) stood at $11.3 billion in 2021, then dropped by 20.23% to $9.1 billion in 2022, then decreased by 14.31% to $7.8 billion in 2023, then dropped by 24.17% to $5.9 billion in 2024, then grew by 28.95% to $7.6 billion in 2025.
- Its Equity Average was $7.6 billion in Q4 2025, compared to $7.0 billion in Q3 2025 and $6.6 billion in Q2 2025.